"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Descriptor ID |
D009369
|
| MeSH Number(s) |
C04
|
| Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 7 | 1 | 8 |
| 2004 | 10 | 3 | 13 |
| 2005 | 7 | 2 | 9 |
| 2006 | 7 | 2 | 9 |
| 2007 | 12 | 2 | 14 |
| 2008 | 10 | 0 | 10 |
| 2009 | 11 | 3 | 14 |
| 2010 | 19 | 5 | 24 |
| 2011 | 14 | 4 | 18 |
| 2012 | 15 | 6 | 21 |
| 2013 | 19 | 4 | 23 |
| 2014 | 17 | 2 | 19 |
| 2015 | 24 | 1 | 25 |
| 2016 | 36 | 2 | 38 |
| 2017 | 31 | 2 | 33 |
| 2018 | 28 | 4 | 32 |
| 2019 | 36 | 8 | 44 |
| 2020 | 49 | 3 | 52 |
| 2021 | 52 | 3 | 55 |
| 2022 | 43 | 2 | 45 |
| 2023 | 27 | 0 | 27 |
| 2024 | 22 | 10 | 32 |
| 2025 | 9 | 0 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Communication Interventions Targeting Both Patients and Clinicians in Oncology: A Systematic Review of Randomized Controlled Trials. Psychooncology. 2025 Mar; 34(3):e70108.
-
Mapping Behavioral Research in Post-Treatment Cancer Care in Sub-Saharan Africa: A Scoping Review. Psychooncology. 2025 Mar; 34(3):e70106.
-
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2025 Feb 25; 95(1):37.
-
Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors. Mol Biol Rep. 2025 Feb 20; 52(1):248.
-
Chromatin Remodulator CHD4: A Potential Target for Cancer Interception. Genes (Basel). 2025 Feb 15; 16(2).
-
National survey of financial burden and experience among patients with cancer and autoimmune disease receiving charitable copay assistance. Cancer. 2025 Jan 15; 131(2):e35721.
-
Screening for Financial Toxicity in Oncology Research and Practice: A Narrative Review. JCO Oncol Pract. 2025 Jan; 21(1):5-11.
-
Financial Toxicity in Older Adults With Cancer and Their Caregivers. JCO Oncol Pract. 2025 Jan; 21(1):92-99.
-
Cost Conversations to Mitigate the Effects of Financial Toxicity in Oncology: Current State, Opportunities, and Barriers. JCO Oncol Pract. 2025 Jan; 21(1):23-28.
-
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.